This is a low-impact scientific update for a micro-cap biotech. The data supports SIL204's mechanistic rationale but does not de-risk the clinical program. Monitor for initiation of the Phase 2/3 trial and any partnership or financing announcements, which are the real catalysts. Given the $2M market cap and historical stock declines, any positive move is likely short-lived without concrete clinical milestones.
Price Chart
Executive Summary
Silexion Therapeutics reported positive preclinical data showing its siRNA candidate SIL204 increases MHC-I expression in KRAS G12R-mutated pancreatic cancer cells, suggesting potential to restore immune visibility and enhance checkpoint inhibitor efficacy. The data is early-stage and does not change the company's clinical or financial trajectory, but provides a mechanistic rationale for future combination immunotherapy strategies.
Key Facts
- SIL204 increased surface MHC-I (HLA-ABC) expression in human KRAS G12R-mutated pancreatic cancer cells at 60 nM, with statistical significance (P<0.05 vs control).
- The finding suggests SIL204 may reverse immune evasion mechanisms in KRAS-driven pancreatic cancer, potentially enabling checkpoint inhibitor responsiveness.
- Data is preclinical (in vitro) and does not alter the company's clinical timeline or regulatory path.
- Silexion is a clinical-stage biotech with no approved products or revenue; market cap is ~$2M.
- The company is advancing SIL204 towards clinical trials in Israel and the EU, with a Phase 2/3 trial planned in locally advanced pancreatic cancer.
Financial Impact
No financial impact; preclinical data only, no revenue or guidance changes.
Risk Factors
- Preclinical findings may not translate to clinical efficacy in humans.
- Company has no approved products and limited cash runway; going-concern risk is high.
- Nasdaq listing compliance remains a risk factor cited in forward-looking statements.
- Historical stock performance shows severe negative drift after prior reports, indicating low investor confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1657 (−7.74%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1657 (+36.95%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1657 (−40.18%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1657 (+40.25%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1657 (+47.89%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1657 (+47.96%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1657 (−33.29%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1657 (+33.29%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1657 (+60.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers